Last reviewed · How we verify
NCT05914818
Proof of Concept of Pediatric and Adolescent EXPLORER V2 Exoskeleton in Children With Neurological and Neuromuscular Disease
NA trial testing EXPLORER V2 in Cerebral Palsy in 30 participants. Completed in 29 September 2023.
29 September 2023
Quick facts
| Lead sponsor | MarsiBionics |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 June 2023 |
| Primary completion | 29 September 2023 |
| Estimated completion | 29 September 2023 |
| Sites | 5 locations across Spain |
Drugs / interventions tested
- EXPLORER V2
Conditions studied
- Cerebral Palsy — all drugs for Cerebral Palsy →
- Acquired Brain Injury — all drugs for Acquired Brain Injury →
- Neuromuscular Diseases in Children — all drugs for Neuromuscular Diseases in Children →
Sponsor
MarsiBionics
Who can join
Adults 2 to 14, any sex, with Cerebral Palsy or Acquired Brain Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to analyze the usability and safety of the prototype gait exoskeleton EXPLORE V2 in children with neurological and neuromuscular disease. Participants will use the exoskeletons in their home and the community and variables regarding safety and usability will be measured and recorded.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05914818
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebral Palsy
Currently open trials in the same condition.
- NCT07524972 — Antenatal Magnesium Sulphate in High-Risk Preterm Patients · Phase 3 · recruiting
- NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
- NCT07466914 — Constipation in Children With Cerebral Palsy · active not recruiting
- NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
- NCT07342348 — Using Power Mobility Training to Promote Arm & Hand Function in Children With Cerebral Palsy · NA · recruiting
Other MarsiBionics trials
Trials by the same sponsor.
- NCT07159360 — Safety, Usability, and Effectiveness of a Gait Exoskeleton for Children and Adolescents With Neurodevelopmental Disorder · NA · not yet recruiting
- NCT06894160 — Safety and Usability of the EXPLORER Exoskeleton in Adults With Neuromuscular Diseases · NA · not yet recruiting
- NCT06765070 — Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Natural Environments · NA · active not recruiting
- NCT06167954 — Safety and Usability of a Robotic Gait Device for Children and Adolescents With Neurological or Neuromuscular Disease in · NA · completed
- NCT05926635 — Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05914818 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MarsiBionics
- Last refreshed: 3 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05914818.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing